Projecten
Meervoudige manifestaties van genetische en niet-genetische factoren in Multiple Sclerosis ontrafelden met een multi-omics benadering om gepersonaliseerde geneeskunde te versnellen KU Leuven
The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations.
MultipleMS will therefore develop, validate, and exploit ...
ECTRIMS Postdoctoraal fellowship onder het Exchange programma van Bieke Broux Universiteit Hasselt
Autonoom en gepersonaliseerd gebruik van het I-TRAVLE concept bij personen met MS & CVA Universiteit Hasselt
Ontwikkeling van op biomateriaal-gebaseerde apparaten voor de behandeling van progressieve MS - een geïntegreerde Pan-Europese aanpak (PMSMatTrain). Universiteit Antwerpen
IMI 2 project: 3TR: Taxonomy, treatment, targets and remission Universiteit Hasselt
Interreg project "Herinneringen". Universiteit Antwerpen
Super-resolutie genomische mapping voor het microbioom KU Leuven
Animals and bacteria have been working together for about as long as they have co-existed, long before the advent of mankind. The bodies of our ancient ancestors offered protected, nutrient-rich habitats for bacteria. In return, animals could take an evolutionary short-cut to developing new capabilities by ‘borrowing’ bacterial genes. Indeed, when gut bacteria assist with the digestion of e.g. dietary fiber, the resulting metabolites will ...
In Silico World: barrières verlagen voor de alomtegenwoordige acceptatie van In Silico Trials KU Leuven
The overall aim of the In Silico World project is to accelerate the uptake of modelling and simulation technologies for the development and regulatory assessment of all kind of medical products. This will be achieved by supporting the trajectory of a number of In Silico Trials solutions through development, validation, regulatory approval, optimisation, and commercial exploitation. These solutions, already developed to different stages, ...
Verbinden van digitale mobiliteitsbeoordeling met klinische uitkomsten voor wettelijke en klinische goedkeuring KU Leuven
Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. ...